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Abstract
Background: The design of appropriate strategies to analyze and interpret linkage results for
complex human diseases constitutes a challenge. Parameters such as power, definition of
phenotype, and replicability have to be taken into account in order to reach meaningful conclusions.
Incorporating data on repeated phenotypic measures may increase the power to detect linkage but
requires sophisticated analysis methods. Using the simulated Genetic Analysis Workshop 13 data
set, we have estimated a variety of systolic blood pressure (SBP) phenotypic measures and
examined their performance with respect to consistency among replicates and to true and false
positive linkage signals.
Results: The whole-genome scan conducted on a dichotomous hypertension phenotype indicated
the involvement of few true loci with nominal significance and gave rise to a high rate of false
positives. Analysis of a cross-sectional quantitative SBP measure performed better, although
genome-wide significance was again not reached. Additional phenotypic measures were derived
from the longitudinal data using random effects modelling for censored data with varying levels of
covariate adjustment. These models provided evidence for significant linkage to most genes
influencing SBP and produced few false positive results. Overall, replicability of results was poor for
loci, representing weak effects.
Conclusion: Longitudinally derived phenotypes performed better than cross-sectional measures
in linkage analyses. Bearing in mind the sample design and size of these data, linkage results that fail
to replicate should not be dismissed; instead, different lines of evidence derived from
complementary analysis methods should be combined to prioritize follow up.
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Background
Lander and Kruglyak [1] proposed that very stringent sig-
nificance thresholds should be achieved before declaring
linkage. However, LOD scores in published whole-
genome scans of complex traits have rarely fulfilled these
criteria. Since the effect size of most loci in complex dis-
eases is expected to be small, it is anticipated that true sus-
ceptibility loci will achieve only modest levels of
significance in the sample sizes of many current studies.
As there are usually insufficient resources to follow up all
loci with modest LOD scores, it is crucial to select those
most likely to contain true susceptibility loci. Replication
of linkage peaks across independent data sets is a com-
monly used strategy to confirm true loci. However, there
are still very few examples of linkage peaks that are repli-
cated uniformly. Phenotype definition, low power to
detect small genetic effects, type I error, and genetic heter-
ogeneity all contribute to inconsistent results.
Phenotype definition is a critical factor that affects the
ability to detect trait loci. The simulated data from Genetic
Analysis Workshop 13 (GAW13) provide enough clinical
and environmental information collected over time to
generate several potential phenotypes aimed at detecting
loci influencing systolic blood pressure (SBP). Incorporat-
ing data on repeated phenotypic measures may increase
the power to detect linkage and will be the only way to
detect genes that influence variation in traits over time.
Obtaining longitudinal data is far more resource-intensive
than collecting cross-sectional data. It is, therefore, impor-
tant to know whether using longitudinal phenotypes does
have more power than cross-sectional phenotypes. The
GAW13 simulated data therefore provide an excellent
opportunity to compare the ability of cross-sectional with
longitudinal phenotypic measures to detect linkage to
known loci.
Our aim was to explore the benefits in terms of power, sci-
entific insight, and replicability of linkage analysis find-
ings of a model-based approach to phenotype
characterization. Several different phenotypic models of
SBP from the GAW13 simulated data were considered,
including a dichotomous hypertension phenotype, a
cross-sectional measure of SBP and longitudinal measures
of 'trait' SBP, adjusted for various sets of covariates. Evi-
dence for linkage for each phenotypic measure was exam-
ined. Irrespective of the phenotype studied, it is still
considered important to replicate evidence of linkage in
an independent data set. Therefore, we analyzed three rep-
licates to examine the consistency of results. All analyses
were done blind to the simulation conditions, which were
provided at the workshop.
Methods
Pedigrees
Replicates 4, 10, and 21 were used in all analysis. Families
with more than 20 individuals were excluded from the
data set to reduce computational time. Two hundred and
seventy seven pedigrees were analyzed with a mean of 11
members (minimum 7 and maximum 20 members). Of
the 3155 subjects in the pedigrees, 33% had genotype
data available.
Systolic blood pressure phenotypes
Six phenotype models describing SBP were defined;
hypertension, a cross-sectional measure of SBP, and four
models derived from longitudinal data, Models 1–4.
Absence or presence of hypertension was used as a quali-
tative phenotype; individuals were defined as affected if
they had a diagnosis of hypertension at any examination.
Eighty-five families, containing enough affected members
with genotype data, contributed to linkage analysis in
each of the three replicates.
Taking the SBP value at the first examination for each sub-
ject generated a cross-sectional measure of systolic SBP.
No one in replicates 4, 10, or 21 was recorded as receiving
antihypertensive treatment at the first time interval; there-
fore, no adjustment for treatment was necessary.
Longitudinal SBP data were analyzed with a subject-spe-
cific approach (e.g., ref [2]). All systolic BP measures taken
over time were included in the analysis. However, some
subjects on some occasions were receiving antihyperten-
sive medications. Since their recorded systolic BP was
lower than it would have been if they had not been on
treatment, these observations were treated as censored.
Therefore, to account for the presence of both repeated
measurements and right censoring, a mixed probit-nor-
mal or Tobit model [3] with a subject-specific random
intercept was estimated using the program GLLAMM
(generalized linear latent and mixed models) in STATA 7
[4].
For an untreated SBP measurement yit made on individual
i at time t the model was specified as yit = βXit + ui + eit,
where Xit is a vector of covariates (including a constant)
that may vary over time, β is a vector of regression coeffi-
cients, ui is a N(0, σu
2) subject-specific random effect, eit
are N(0, σe
2) disturbance terms with corr(u,e.) = 0 for all t
and corr(e.s,e.t) = 0 for s ≠ t. For censored observations Pr[Y
>yit] = Φ ((βXit + ui - yij) / σe,1), where Φ(.,1) is the standard
normal cumulative density function.
The empirical Bayes' estimates of the individual random
effects (the subject level residuals { }) were extracted for
use as adjusted longterm SBP phenotypes for input to
SOLAR [5]. Fitted to males and females separately, four
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different adjustments for covariates were considered:
Model 1: age, age squared and body mass index; Model 2:
covariates in Model 1 plus cohort; Model 3: covariates in
Model 2 plus smoking and alcohol consumption; Model
4: covariates in Model 3 plus cholesterol level and fasting
glucose. Covariates were selected for inclusion in a step-
wise manner, starting with subject-specific factors known
to strongly affect SBP, then an allowance for any possible
cohort effect, followed by further environmental covari-
ates. Finally, we included possible intermediate pheno-
types that contribute to the variation in SBP, including
such covariates may reduce the power to detect linkage for
genes contributing to these intermediate phenotypes.
The models for repeated censored data yielded consistent
covariate effects across replicates for cigarettes per day and
the absence of effect for alcohol, moderate consistency for
cholesterol, and weak consistency for glucose.
Heritability and linkage analysis
Heritability estimates were obtained using variance com-
ponents analysis as implemented in the SOLAR package
[5]. Multipoint quantitative linkage analyses were con-
ducted on the cross-sectional SBP phenotype and the
standardized residuals for the longitudinal systolic SBP
values.
GENEHUNTER version 2 [6] was used to carry out a non-
parametric linkage (NPL) analysis of the whole genome,
treating hypertension as a qualitative trait, as described
above.
LOD scores > 1 were considered as nominal evidence of
linkage, LOD scores > 2.2 as suggestive evidence, LOD
scores > 3.6 as genome-wide evidence and LOD scores >
5.4 as confirmed linkage.
Pedigreed disequilibrium test (PDT) analysis
Microsatellite markers under areas of increased allele shar-
ing (p < 0.1) were tested for evidence of association with
the hypertension phenotype. The PDT method [7] was
used, as this is a test for linkage and association in general
pedigrees and can currently only be applied to qualitative
data. In total 99 markers were analyzed.
Results
Hypertension phenotype
No NPL scores achieving genome-wide significance were
detected using hypertension as a trait. All replicates pro-
duced linkage peaks with a NPL score > 1. The most signif-
icant results were on chromosomes 15 (109 cM), 18 (28–
70 cM) and 21 (23–50 cM) for replicates 4, 10, and 21,
respectively. The former two loci did not contain true trait
loci. There was very little consistency between replicates,
with only chromosome 21 showing some evidence of
linkage in more than one replicate. Table 2 shows maxi-
mum LOD scores achieved for genes affecting SBP.
SBP phenotypes models
All of the phenotypic measures of SBP were highly herita-
ble (>70%) and are listed in Table 1. All phenotypic meas-
ures of SBP produced LOD scores > 1 for all replicates. The
maximum LOD scores achieved for each trait at each gene
locus are shown in Table 2. All but one of the loci influ-
encing SBP was detected in at least one replicate and in
general evidence for linkage was greater using the
longitudinally derived phenotypes. The genes Gb35 on
chromosome 13 and Gs11 on chromosome 15 were only
detected by the longitudinal phenotypes.
There was little overall consistency in loci detected
between replicates as shown in Table 3. The linkage region
on chromosome 21 (20–50 cM) was the only region that
showed evidence of linkage in all three replicates. Genes
Gb35 on chromosome 13 and Gs11 on chromosome 15
were only detected in a single replicate (4 and 21
respectively).
Table 1: Heritability estimates obtained from SOLAR
Replicate
Model 4 10 21
SBP + covariates 87.9% 70.7% 74.6%
Model 1 80.4% 76.5% 78.3%
Model 2 79.9% 76.6% 78.2%
Model 3 75.4% 73.8% 73.0%
Model 4 76.5% 76.0% 74.9%BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S26
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PDT analysis
To provide further evidence of linkage for potential link-
age regions, microsatellite markers mapping to weak
regions of linkage on chromosomes 2, 5, 10, 11, 13, 15,
16, 20, and 21 were tested for evidence of association to
hypertension using the PDT method. Seven markers
showed evidence of preferential transmission (p < 0.05)
using the sum and/or average PDT result. Of these, two
mapped to true disease loci near Gb35 and Gs12.
Discussion
Six phenotypic measures of SBP were generated for the
purposes of this analysis. The two cross-sectional meas-
ures required only one data point per subject. Incorporat-
ing all longitudinal data is likely to increase the power to
detect linkage, but there are several possible methods that
could be applied to derive longitudinal phenotypes. The
four adjusted 'trait' SBP measures derived in this analysis
were based on all the available SBP measures for each
individual and were estimated as subject-specific random
intercepts using the program GLLAMM. This approach is
appealing because it allows adjustment for a treatment
effect to be included in the model and, by sequentially
including covariates, the effect of different covariate
adjustments on linkage results can be observed. Estima-
tion is by maximum likelihood using adaptive
quadrature, an approach that has good properties for a
wide range of measures and sampling schemes, is very
flexible, and not especially computationally demanding
(a few minutes on a personal computer).
The categorical hypertension phenotype showed the least
evidence of linkage to any of the true loci. Two of the most
significant regions of linkage identified using
hypertension as a qualitative trait (chromosomes 15 and
18 for replicates 4 and 10, respectively) only showed any
Table 2: Max LOD scores reached in any replicate for genes affecting blood pressure for each phenotypic measure of SBP. Peak LOD 
within 20 cM of true location, using the sex averaged map.
Phenotype
Gene Location Hypertension SBP 1st exam Model 1 Model 2 Model 3 Model 4
Gb34 Chr 5: 176.1 cM NDA 1.8 ND ND ND ND
Gb35 Chr 13: 85.2 cM ND ND 2.8 5.2 ND ND
Gb36 Chr 7: 47.5 cM ND ND ND ND ND ND
Gb37 Chr 21: 29.1 cM 1.4 2.4 9.7 9.7 11 11.1
Gs10 Chr 21: 53.6 cM 1.4 2.4 10.4 10.3 11 11.1
Gs11 Chr 15: 4.5 cM ND ND 2.2 2.2 1.5 2.1
Gs12 Chr 21: 29.5 cM 1.4 2.4 9.7 9.7 11 11.1
False positives 1.5 (Chr 3) 2.7 (Chr 5) 1.7 (Chr 9) 1.7 (Chr 9) 1.4 (Chr 11)
1.6 (Chr 5) 1.5 (Chr 8) 2.3 (Chr 11) 2.3 (Chr 11)
1.4 (Chr 9) 3.4 (Chr 12)
1.6 (Chr 18)
AND: no evidence of linkage detected at LOD > 1.3.
Table 3: Evidence for linkage in more than one replicate for each gene affecting SBP
Number of replicates with evidence of linkage
Gene Variance Mean Same phenotypic 
measure
Any phenotypic 
measure
PDT analysis
G b 3 4 0 . 2 5 0110
G b 3 5 0 . 1 5 0111
G b 3 6 0 . 1 0000
Gb37A 0 . 4 0230
G s 1 0 0 . 1 2 4 0 . 3 4 2 331
G s 1 1 0 . 0 5 8 0 . 1 3 7 110
G s 1 2 0 . 0 1 5 0 . 0 8 4 230
AThe variance and mean of Gb37 is the locus effect on diastolic blood pressure.BMC Genetics 2003, 4 http://www.biomedcentral.com/1471-2156/4/s1/S26
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evidence for linkage in a single replicate and were not con-
sistent with any other measure of SBP. These loci are in
fact false positive results. The relatively poor performance
of the hypertension phenotype may, however, be related
to the general population sample design that yielded a
rather small effective sample size (85 families per repli-
cate). To overcome the loss of power inherent to such a
study design, the PDT method was employed to provide
complementary evidence toward the involvement of the
implicated chromosomal regions. The quantitative cross-
sectional measure derived from SBP at first exam detected
three genes at suggestive evidence of linkage, one with a
LOD score 1.8, and produced three false positive results
on chromosomes 5, 8, and 12. None of the LOD scores
reached genome-wide significance and there was little
consistency between replicates. The longitudinally
derived phenotypes were superior to the cross-sectional
measure both in terms of the number of loci detected and
the magnitude of the evidence for linkage. These pheno-
types were able to detect five loci influencing SBP at sug-
gestive evidence of linkage, four of these at a genome-wide
significance level. In general, LOD scores also improved
with adjustment for covariates, although this was not
always the case, suggesting that using all the models pro-
vided the most information about linkage at any given
locus.
Because this analysis was performed blind to the answers,
it was not possible at the time to determine which linkage
peaks corresponded to true trait loci. This made the initial
interpretation of the results difficult because many of the
LOD scores were modest and there were inconsistencies in
results between replicates. Deciding which loci are true or
false is a difficult problem for researchers when faced with
real whole-genome scan results. We therefore prioritized
loci more likely to be true using the following criteria: evi-
dence of linkage in more than one replicate, evidence of
linkage with more than one phenotype, and evidence of
linkage and association with a nearby microsatellite
marker. Having followed this process, we concluded that
we would suggest that chromosome 21 harbors at least
one locus influencing BP and we would predict that the
regions on chromosomes 5, 11, and 13 would also be
worthy of further investigation. Interestingly, the chromo-
some 21 loci, detected through the use of each of the phe-
notypic measures, cumulatively accounted for 54% of the
variance. We would therefore have followed up all the
true loci except Gb7, which we did not detect, and Gs11,
because it produced evidence for linkage in just a single
replicate. We would also have followed up one false posi-
tive result (chromosome 11) and not followed up the one
on chromosome 12.
The aim of using the standardized residuals from the lon-
gitudinal BP models was to increase power to detect link-
age to SBP. We used a random intercept residual and did
not explore using random slope residuals that might have
detected genes for late onset high SBP. While such residu-
als are easily estimable within our approach, we consid-
ered the a priori scientific case for them to be less
convincing. It is, therefore, perhaps surprising that we
were able to detect the three slope genes influencing SBP
with such high LOD scores. Two of these slope genes
mapped to chromosome 21; Gb37 also mapped to the
same locus as Gs12 and explained 40% of the variance of
diastolic blood pressure. Because diastolic blood pressure
directly affects SBP, it is not clear exactly what the linkage
is picking up on chromosome 21.
Conclusions
This analysis of the GAW13 simulated data has demon-
strated that longitudinally derived phenotypes have more
power to detect baseline and slope genes than cross-sec-
tional measures of the same trait, thus suggesting that they
are likely to be essential for many genetic studies. The suc-
cessful identification of all but one true trait loci using
GLLAMM indicates that it is an effective method for deriv-
ing powerful longitudinal phenotypes. Furthermore, the
limited overlap observed among replicates suggests that
unreplicated linkage results should not be lightheartedly
dismissed, especially when they may represent weak
effects, as is the case in complex diseases. Complementary
evidence derived from diverse data analyses should, there-
fore, drive the prioritization of linkage peaks for follow-
up, in order to maximize use of the available resources to
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